Virtual Care for the Longitudinal Management of Chronic Conditions: A Systematic Review

November 2021

Prepared for:
Department of Veterans Affairs
Veterans Health Administration
Health Services Research & Development Service
Washington, DC 20420

Prepared by:
Evidence Synthesis Program (ESP) Center
Durham VA Healthcare System
Durham, NC
Karen M. Goldstein, MD, MSPH, Co-Director
Jennifer M. Gierisch, PhD, MPH, Co-Director

Authors:
Conor Walsh, MD
Allison A. Lewinski, PhD, MPH, RN
Sharron Rushton, DNP, MS, RN, CCM, CNE
Diana Soliman, MD
Scott M. Carlson, MD
Matthew W. Luedke, MD
David Halpern, MD, MPH
Matthew Crowley, MD
Ryan Shaw, PhD, RN
Jason Sharpe, PT, PhD
Anastasia-Stefania Alexopoulos, MBBS, MHS
Amir Alishahi Tabriz, MD, MPH, PhD
Jessica R. Dietch, PhD
Diya M. Uthappa, BS
SooHyun Hwang, MPH
Katharine A. Ball Ricks, PhD, MPH, MS
Sarah Cantrell, MLIS, AHIP
Andrzej S. Kosinski, PhD
Belinda Ear, MPH
Adelaide M. Gordon, MPH
Jennifer M. Gierisch, PhD, MPH
John W. Williams Jr., MD, MHSc
Karen M. Goldstein, MD, MSPH
PREFACE

The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted health care topics of importance to clinicians, managers, and policymakers as they work to improve the health and health care of Veterans. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The program comprises three ESP Centers across the US and a Coordinating Center located in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Center. The Coordinating Center was created to manage program operations, ensure methodological consistency and quality of products, and interface with stakeholders. To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee composed of health system leadership and researchers. The program solicits nominations for review topics several times a year via the program website.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Nicole.Floyd@va.gov.


This report was prepared by the Evidence Synthesis Program Center located at the Durham VA Medical Center, Durham, NC, directed by Karen M. Goldstein, MD, MSPH, and Jennifer M. Gierisch, PhD, MPH, and funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development.

The findings and conclusions in this document are those of the author(s) who are responsible for its contents and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.
ACKNOWLEDGMENTS

This topic was developed in response to a nomination by Carolyn Turvey, Office of Rural Health, for the purpose of informing future research and to support adoption of effective virtual care service models. The scope was further developed with input from the topic nominators (ie, Operational Partners), the ESP Coordinating Center, the review team, and the Technical Expert Panel (TEP).

In designing the study questions and methodology at the outset of this report, the ESP consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Operational Partners

Operational partners are system-level stakeholders who have requested the report to inform decision-making. They recommend TEP participants; assure VA relevance; help develop and approve final project scope and timeframe for completion; provide feedback on draft report; and provide consultation on strategies for dissemination of the report to field and relevant groups.

Carolyn Turvey, PhD
Office of Rural Health
Rural Health Resource Center, Iowa City

Technical Expert Panel (TEP)

To ensure robust, scientifically relevant work, the TEP guides topic refinement; provides input on key questions and eligibility criteria, advising on substantive issues or possibly overlooked areas of research; assures VA relevance; and provides feedback on work in progress. TEP members are listed below:

Bryan Batch, MD
Durham VA Medical Center
Durham, NC

Hayden Bosworth, PhD
Durham VA Medical Center
Durham, NC

Marla Clayman, PhD, MPH, BA
Edith Nourse Rogers Memorial Veterans Hospital
Bedford, MA

Christopher Mosher, MD
Duke University Medical Center
Durham, NC
Peer Reviewers

The Coordinating Center sought input from external peer reviewers to review the draft report and provide feedback on the objectives, scope, methods used, perception of bias, and omitted evidence. Peer reviewers must disclose any relevant financial or non-financial conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The Coordinating Center and the ESP Center work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.
# TABLE OF CONTENTS

Acknowledgments .................................................................................................................................................. ii

Executive Summary ............................................................................................................................................... 1

   Introduction .................................................................................................................................................. 1
   Methods ..................................................................................................................................................... 2
   Results ....................................................................................................................................................... 3
   Discussion .................................................................................................................................................. 6
   Abbreviations Table .................................................................................................................................... 9

Evidence Report .................................................................................................................................................. 10

Introduction .................................................................................................................................................... 10

Methods ......................................................................................................................................................... 12

   Topic Development .................................................................................................................................. 12
      Key Questions ....................................................................................................................................... 12
      Conceptual Model ............................................................................................................................... 14
   Search Strategy ........................................................................................................................................ 14
   Study Selection .......................................................................................................................................... 15
   Data Abstraction ...................................................................................................................................... 17
   Risk of Bias (Quality) Assessment .......................................................................................................... 17
   Data Synthesis ......................................................................................................................................... 18
      Analysis of Subgroups or Subsets ......................................................................................................... 18
      Grading the Certainty of Evidence ...................................................................................................... 18
      Peer Review ......................................................................................................................................... 19

Results ............................................................................................................................................................ 20

   Literature Flow ........................................................................................................................................ 20
   Key Question 1 ....................................................................................................................................... 23
      1A: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of congestive heart failure (CHF) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)? .................. 23
      1B: Does this effect differ by race/ethnicity, gender, age, and rural status? ................................. 23
   Key Points ............................................................................................................................................... 23
   Detailed Findings: KQ 1a ...................................................................................................................... 23
   Quality of Evidence for KQ 1a ............................................................................................................... 24
   Detailed Findings: KQ 1b ...................................................................................................................... 24
Key Question 2 ......................................................................................................................... 24

2a: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of chronic obstructive pulmonary disease (COPD) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)? ....................................................................................................................................... 24

2b: Does this effect differ by race/ethnicity, gender, age, and rural status? ............................. 24

Key Question 3 ......................................................................................................................... 25

3a: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of Type 2 diabetes mellitus (T2DM) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)? .............................................................................................. 25

3b: Does this effect differ by race/ethnicity, gender, age, and rural status? ............................. 25

Key Points .................................................................................................................................. 25

Characteristics of Included Studies ....................................................................................... 25

Detailed Findings: KQ 3a ..................................................................................................... 26

Quality of Evidence for KQ 3a ............................................................................................. 28

Detailed Findings: KQ 3b ..................................................................................................... 30

Key Question 4: What are the adverse effects of synchronous virtual care for chronic management of CHF, COPD, and T2DM as compared to in-person care (or compared to phone if synchronous video care) on patients (ie, hypoglycemic events), clinical team members (ie, burnout), and clinics (ie, increase in resource costs)? ........................................ 31

Detailed Findings: KQ 4 ....................................................................................................... 31

Summary and Discussion ........................................................................................................... 32

Summary of Evidence by Key Question .................................................................................. 32

Prior Systematic Reviews ...................................................................................................... 33

Horizon Scan .......................................................................................................................... 34

Clinical And Policy Implications .......................................................................................... 35

Limitations ............................................................................................................................... 36

Research Gaps ......................................................................................................................... 37

Conclusions ............................................................................................................................. 39

References .................................................................................................................................... 40

FIGURES AND TABLES

Figure 1. Virtual Care Conceptual Model ................................................................................ 14

Table 1. Study Eligibility .......................................................................................................... 15

Figure 2. Literature Flow Chart ................................................................................................. 21
## ABBREVIATIONS TABLE

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1c</td>
<td>Hemoglobin A1c</td>
</tr>
<tr>
<td>AHRQ</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CRT-D</td>
<td>Cardiac Resynchronization Therapy-Defibrillator</td>
</tr>
<tr>
<td>EPOC</td>
<td>Effective Practice and Organization of Care</td>
</tr>
<tr>
<td>ER</td>
<td>Emergency room</td>
</tr>
<tr>
<td>ESP</td>
<td>Evidence Synthesis Program</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>ICD</td>
<td>Implanted Cardioverter Defibrillator</td>
</tr>
<tr>
<td>KQ</td>
<td>Key question</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>OECD</td>
<td>Organization for Economic Co-operation and Development</td>
</tr>
<tr>
<td>ORH</td>
<td>Office of Rural Health</td>
</tr>
<tr>
<td>PICOTS</td>
<td>Population, intervention, comparator, outcome, timing, setting</td>
</tr>
<tr>
<td>PRESS</td>
<td>Peer Review of Electronic Search Strategies</td>
</tr>
<tr>
<td>PRISMA</td>
<td>Preferred Reporting Items for Systematic Reviews and Meta Analyses</td>
</tr>
<tr>
<td>PROSPERO</td>
<td>The International Prospective Register of Systematic Reviews</td>
</tr>
<tr>
<td>RFA</td>
<td>Request for applications</td>
</tr>
<tr>
<td>RM</td>
<td>Remote monitoring</td>
</tr>
<tr>
<td>ROB</td>
<td>Risk of Bias</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>TEP</td>
<td>Technical Expert Panel</td>
</tr>
<tr>
<td>VHA</td>
<td>Veterans Health Administration</td>
</tr>
<tr>
<td>VVC</td>
<td>VA Video Connect</td>
</tr>
</tbody>
</table>
EVIDENCE REPORT

INTRODUCTION

As both the largest integrated health system and largest provider of telehealth in the country, the Veterans Health Administration (VHA) has a particular interest in understanding how best to implement and utilize virtual care. VHA has long embraced virtual care as part of its mission to “serve all who have served” regardless of their socioeconomic and geographic circumstances. Having begun conducting “virtual care” in the 1960s when doctors first communicated with patient’s via TV screens, VHA has since provided over 2.6 million episodes of care to more than 900,000 Veterans in 2019 and has distributed over 50,000 data- and video-enabled iPads for Veterans throughout the country. Virtual care within VHA includes services such as MyHealtheVet secure messaging, the Home Telehealth program that combines case management principles with remote monitoring to improve access and coordinate care, and the VA Video Connect (VVC) video platform for synchronous visits within both specialty and primary care.

Increasing Veteran access to care via virtual care has been an integral part of VHA’s strategy for improving chronic disease management for a population that is on average older and sicker than their civilian counterparts. Given the importance that virtual care has for Veteran care even beyond the COVID-19 pandemic, understanding the strengths and limitations associated with synchronous virtual care will be critical in shaping how VHA utilizes virtual care going forward.

Virtual care can be defined as the use of technology to facilitate an interaction between a patient and their health care team across distance or time. This broad definition includes a wide variety of technologies and interventions, such as text messages and email communications, asynchronous remote monitoring, and synchronous (ie, real-time) phone/video visits. Given the large heterogeneity of care delivery that falls under the umbrella of virtual care, its impact is dependent upon the specific modality and application as well as the patient populations involved. For example, a systemic review and evidence map of virtual care literature in 2016 published by the Agency for Healthcare Research and Quality (AHRQ) which focused largely on virtual care when used in addition to in-person care found consistent evidence of benefit for virtual care with counseling and remote monitoring of chronic conditions but found unclear evidence supporting virtual care for clinical consultation or maternal and child health among other clinical circumstances. Importantly, specific virtual care modalities can have different impacts depending on the clinical situation and patient population. For example, chronic conditions which depend on physical assessment to determine clinical status (eg, congestive heart failure [CHF] or chronic obstructive pulmonary disease [COPD]) or the presence of complications (eg, diabetes mellitus) may have different challenges compared to other conditions which can largely be managed without physical exam (eg, mental health). Understanding when virtual care is most effective will be particularly important as we try to right size the implementation of virtual modalities after the initial dramatic increase due the COVID-19 pandemic.

COVID-19 has had a profound impact on ambulatory care delivery. The onset of the COVID-19 pandemic in early 2020 led to an unprecedented growth in synchronous virtual care delivery via phone and video encounters as a means of mitigating the risk of viral transmission for both patients and clinicians. The impact of COVID-19 on ambulatory care was so profound that it is estimated that outpatient visits across the entire country decreased by nearly 60% by the end of
March. In response, many health systems rapidly converted 70% or more of their outpatient visits to virtual care delivery via phone or video. To support the US health care system during the crisis, the Centers for Medicare and Medicaid Services issued an emergency ruling aimed at decreasing regulatory requirements for virtual care and created payment parity between in-person care and virtual care delivered via phone or video. Although in-person care visits have since increased, as more has become known about COVID-19 transmission and prevention practices, virtual care continues to have a much larger role in outpatient care than prior to the pandemic. Even after the pandemic recedes, it is likely that synchronous virtual care will remain a large part of ambulatory care. Therefore, a close examination of this specific model of virtual care and its strengths and limitations is warranted.

Prior to the pandemic, virtual care was used to shift workload from clinicians to other clinical team members and to supplement rather than replace in-person care. For example, remote monitoring has been combined with phone calls from virtual care nurses or case managers to supplement care for patients with CHF and type 2 diabetes mellitus (T2DM). In essence, many prior virtual care studies focused on augmentation of usual care, whereas now it is important to understand which patients and conditions can be managed by clinicians with only limited in-person evaluation. In this context, there are many unanswered questions. First, does synchronous virtual care result in similar clinical outcomes compared with in-person care? Second, in what context is virtual care appropriate as a substitute for in-person care? Furthermore, what are the risks for harm such as missed or delayed diagnoses, increased health care disparities, and worse clinical outcomes? Understanding the evidence for benefit and harm with this specific application of virtual care will help shape current practice and inform future research and investments in virtual care.

Particularly important within VHA is the chronic management of CHF, COPD, and T2DM, as these are among the most common and costly conditions affecting nearly 5%, 10%, and 25% of all Veterans, respectively. In addition, these conditions typically require physical assessment to establish disease status and the presence and extent of exacerbations. Despite the reliance on physical assessment, during the COVID pandemic we experienced a near complete shift to managing care of such conditions virtually. Moving forward, we will need to match the best care modality by condition for specific patient populations. This is a priority within VHA. Thus, our systematic review examined the use of virtual care as a substitute for in-person care in the context of chronic management for CHF, COPD, and T2DM.
METHODS

We followed a standard protocol for this review developed in collaboration with operational partners and a technical expert panel. The PROSPERO registration number is CRD42021239756. The protocol was developed prior to conducting the review, and there were no significant deviations after registration. Each step was pilot tested to train and calibrate study investigators. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.21

TOPIC DEVELOPMENT

This topic was proposed by the leadership of the Office of Rural Health (ORH). Key questions as outlined below were driven in particular by the ORH’s desire to better understand virtual care access and use by marginalized patient populations given inequities exposed by shifts in care during the COVID-19 pandemic and concerns about the potential worsening of existing or creation of new sources of health disparities. Findings will be used to inform the development of Request for Applications (RFAs) on virtual care implementation research and to support the adoption of effective virtual care service models.

Key Questions

The Key Questions (KQs) for this report were:

KQ 1a: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of congestive heart failure (CHF) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)?

KQ 1b: Does this effect differ by race/ethnicity, gender, age, and rural status?

KQ 2a: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of chronic obstructive pulmonary disease (COPD) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)?

KQ 2b: Does this effect differ by race/ethnicity, gender, age, and rural status?

KQ 3a: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of type 2 diabetes mellitus (T2DM) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)?

KQ 3b: Does this effect differ by race/ethnicity, gender, age, and rural status?
KQ 4: What are the adverse effects of synchronous virtual care for chronic management of CHF, COPD, and T2DM as compared to in-person care (or compared to phone if synchronous video care) on patients (ie, hypoglycemic events), clinical team members (ie, burnout), and clinics (ie, increase in resource costs)?
Conceptual Model

Figure 1 depicts our conceptual model. Our analysis of virtual care begins with the patient who has a chronic disease (eg, CHF, COPD, or T2DM), and the clinical visit (eg, purposeful interaction between the prescribing clinician and patient), which encompasses all activities between the prescribing clinician and patient. Following review of the literature and team discussions, we are considering the virtual care modality (eg, telephone, video, in-person) to mediate the relationship between the clinical visit and prespecified clinical- and system-level outcomes. Of note, we acknowledge that individual patient characteristics (eg, race/ethnicity, gender, age, rural status) may moderate the relationship between the modality in which the clinical visit occurs and any clinical- and system-level outcomes. Given the focus of our key questions, we also specified that the care delivered virtually should be for clinical activities provided by a prescribing clinician such as evaluation, diagnosis, or medication prescription and not for the provision of self-management education and/or other support provided adjunctively by a clinical team member other than the prescribing clinician (eg, nurse care manager) as such interventions have been previously evaluated.7 The conceptual model outlines the population, outcomes, mediation effect of the modality, moderation effect of patient characteristics, and any adverse effects. The virtual care interventions map to our operationalized definition of virtual care and also include important contextual elements such as delivery mode (eg, telephone, video, in-person), dose (eg, duration and frequency of contact), and clinical context of care provision.

Figure 1. Virtual Care Conceptual Model

SEARCH STRATEGY

In collaboration with an expert medical librarian, we conducted a primary literature search from inception to February 7, 2021, of MEDLINE® (via Ovid®), Embase (via Elsevier). We used database-specific subject headings and keywords searched in the titles and abstracts (Appendix A). The search strategies were peer reviewed by another expert medical librarian prior to execution using the Peer Review of Electronic Search Strategies (PRESS) Checklist.22 We hand-searched previous systematic reviews conducted on this or a related topic for potential inclusion.
STUDY SELECTION

Studies identified through our primary search were classified independently by 2 investigators for relevance to the KQs based on title and abstract from our *a priori* established eligibility criteria. All citations classified for inclusion by at least 1 investigator were reviewed at the full-text review level. The citations designated for exclusion by 1 investigator at the title and abstract level underwent screening by a second investigator. If both investigators agreed on exclusion, the study was excluded. All articles meeting eligibility criteria were included for data abstraction. All results were tracked in an electronic database (for referencing, EndNote®, Clarivate Analytics, Philadelphia, PA; for data abstraction, DistillerSR; Evidence Partners Inc., Manotick, ON, Canada).

Table 1 describes the study eligibility criteria organized by PICOTS elements (population, intervention, comparator, outcome, timing, setting) and other criteria such as study design, language, and publication type. Specifically, for the virtual care intervention we sought to identify studies that evaluated the effect of synchronously delivered care for relevant chronic conditions that occurred over ≥ 2 encounters and in which some or all in-person care is supplanted by virtual care (*ie*, phone or video). The virtual care must be delivered remotely by a clinician with a scope of practice that includes independent prescribing, diagnosis, and/or chronic management (*ie*, physician, nurse practitioner, physician assistant, clinical pharmacist) for a patient who is not physically present in the same clinic (*ie*, teleconsultation, video conferencing) and that is administered within the context of longitudinal care provision (even if individual visits are for acute concerns). Interventions are not required to be exclusively virtual care provided by a clinician as described above; rather, they may include the above with other asynchronous virtual care tools (*eg*, remote monitoring systems), virtual care manager support, or in-person visits with a prescribing clinician as well. Remote monitoring that triggers synchronous care would be eligible if remote monitoring occurs in both treatment and comparison arm and visits are with a prescribing clinician. We did not include studies that tested virtual care interventions in which the virtual care component was care provided *in addition* to regular in-person care rather than as a substitute.

**Table 1. Study Eligibility**

<table>
<thead>
<tr>
<th>Study Characteristic</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
</table>
| Population           | Adults (≥ 18 years of age) with the following chronic conditions:  
  • CHF  
  • COPD  
  • T2DM; at least 75% if a mix of type 1 and type 2  
  • Clinicians/clinics conducting virtual care for chronic conditions if relevant to harms | Inpatient populations (*eg*, tele-ICU)  
  • Patients receiving care in an ER or tele-urgent care setting  
  • Intervention limited only to the management of complications of these chronic conditions such as stroke, retinopathy, neuropathy, and foot ulcers |
<table>
<thead>
<tr>
<th>Study Characteristic</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td>• Synchronous care delivered over ≥ 2 encounters for the long-term management of relevant chronic conditions in which some or all in-person care is supplanted by virtual care (i.e., phone or video) and which is delivered remotely by an independently licensed clinician&lt;br&gt;• May include asynchronous virtual care tools (e.g., remote monitoring systems), if in both arms.</td>
<td>• Supplemental nurse care management&lt;br&gt;• Virtual care interventions that don’t involve synchronous care delivered by a clinician to a patient (e.g., one-way automated texts, reminder systems,)&lt;br&gt;• Tele-cardiac or tele-pulmonary rehabilitation</td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>In-person care without any virtual care delivery, or care delivered by telephone if compared to video</td>
<td>No comparator</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>• Key clinical outcomes (e.g., medication adherence, quality of life, depression) and by condition:&lt;br&gt;  o CHF (e.g., NYHA class/symptoms)&lt;br&gt;  o COPD (e.g., exercise tolerance, dyspnea)&lt;br&gt;  o T2DM (e.g., A1c)&lt;br&gt;• Clinical utilization (i.e., hospitalization, hospital re-admissions, emergency room visits/urgent care)&lt;br&gt;• Adverse effects (e.g., hypoglycemic episodes, inappropriate treatment, clinician burnout)</td>
<td>Any outcomes not listed</td>
</tr>
<tr>
<td><strong>Timing</strong></td>
<td>No limit</td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Any outpatient setting (i.e., general medical or specialty care clinic)</td>
<td>Intervention delivered primarily in hospital inpatient setting (including emergency room)</td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>• EPOC criteria studies that have prospective data collection:&lt;br&gt;  o Randomized trials&lt;br&gt;  o Non-randomized trials&lt;br&gt;• Controlled before-after studies&lt;br&gt;• Interrupted time-series studies or repeated measures studies</td>
<td>• Not a clinical study (e.g., editorial, letter to an editor)&lt;br&gt;• Uncontrolled clinical study&lt;br&gt;• Qualitative studies&lt;br&gt;• Prospective or retrospective observational studies&lt;br&gt;• Clinical guidelines&lt;br&gt;• Measurement or validation studies&lt;br&gt;• Studies that look at mixed chronic conditions if results for specified conditions are not reported separately</td>
</tr>
<tr>
<td><strong>Countries</strong></td>
<td>OECD*</td>
<td>Non-OECD</td>
</tr>
</tbody>
</table>
Virtual Care for the Longitudinal Management of Chronic Conditions  

**Evidence Synthesis Program**

<table>
<thead>
<tr>
<th>Study Characteristic</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication types</td>
<td>Full publication in a peer-reviewed journal</td>
<td>Letters, editorials, reviews, dissertations, meeting abstracts, protocols without results</td>
</tr>
</tbody>
</table>

**Abbreviations.** A1c = hemoglobin A1c; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; EPOC = effective practice and organization of care; ER = emergency room; ICU = intensive care unit; NYHA = New York Heart Association; T2DM = type 2 diabetes mellitus.

²OECD = Organization for Economic Co-operation and Development includes Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Latvia, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, and United States.

**DATA ABSTRACTION**

Data from published reports were abstracted into a customized DistillerSR database by 1 reviewer and over-read by a second reviewer. Disagreements were resolved by consensus or by obtaining a third reviewer’s opinion. Data elements included descriptors to assess applicability, quality elements, intervention details, and outcomes including adverse events.

Key characteristics abstracted included participant descriptors (eg, race/ethnicity, gender, age, rural status), intervention characteristics (eg, clinician type, virtual care modality), comparator, and outcomes. We abstracted all outcomes used to evaluate virtual care but prioritized outcomes identified a priori in collaboration with our stakeholders for analysis. Multiple reports from a single study were treated as a single data point, prioritizing results based on the most complete and appropriately analyzed data. When critical data were missing or unclear in published reports, we requested supplemental data from the study authors. Key features relevant to applicability included the match between the sample and target populations (eg, age, Veteran status).

For details of study characteristics, see Appendix B. Appendix C presents details of the intervention characteristics. Appendix D lists all outcomes reported in the included studies, and Appendix E lists excluded studies and the reason for exclusion.

**RISK OF BIAS (QUALITY) ASSESSMENT**

Quality assessment was done by the investigator abstracting or evaluating the included article and was over-read by a second, highly experienced investigator. Disagreements were resolved by consensus between the 2 investigators or, when needed, by arbitration by a third investigator.

For randomized, non-randomized, and controlled before-after studies, we used criteria from the Cochrane EPOC ROB tool. These criteria are adequacy of randomization and allocation concealment; comparability of groups at baseline; blinding; completeness of follow-up and differential loss to follow-up; whether incomplete data were addressed appropriately; validity of outcome measures; protection against contamination; selective outcomes reporting; and conflict of interest. We assigned a summary ROB score (low, unclear, high) to individual studies, defined as follows:

- Low ROB: Bias, if present, is unlikely to alter the results seriously.
Unclear ROB: Information required to determine ROB was not clearly specified in the peer-reviewed paper or unable to be obtained to make a judgment.

High ROB: Bias may alter the results seriously.

DATA SYNTHESIS

We summarized the primary literature using relevant data abstracted from the eligible studies. Summary tables describe the key study characteristics of the primary studies: study design, patient demographics, and details of the intervention and comparator. Because of the conceptual heterogeneity of the identified study interventions, we did not complete a quantitative synthesis (i.e., meta-analysis) to estimate summary effects. Rather we describe the findings from included studies narratively focusing on documenting and identifying patterns in efficacy and safety of the interventions across conditions and outcome categories.

Continuous outcomes were summarized using the mean difference (follow-up minus baseline) when all studies reported the outcome using the same scale. For studies not directly reporting mean and standard deviation of patient differences, we used difference in means between follow-up and baseline. For 1 study, we computed standard deviation of difference based on reported p-value for difference between the 2 arms, assuming the same correlation between follow-up and baseline in each arm. When studies reported only medians and ranges, we translated them to means and standard deviations and if a study reported only baseline standard deviation, assumed the same standard deviation at follow-up. Finally, in absence of other information, we assumed 0.5 correlation between follow-up and baseline.

Analysis of Subgroups or Subsets

We sought to consider variations of effect by subgroup of interest, specifically age, rurality, gender, and race/ethnicity. Prespecified potential effect modifiers of interest included study design characteristics (e.g., allocation concealment), disease context (i.e., CHF, COPD, T2DM), and potentially intervention type (e.g., virtual care modality). Regarding patient-level characteristics of interest (i.e., race/ethnicity, gender, age, rural status), we looked for analyses conducted within the primary literature that sought to identify effect modification (e.g., subgroup analyses, regression model explanatory variables). We narratively considered the representation of subgroups within identified studies in comparison to the VA population.

GRADING THE CERTAINTY OF EVIDENCE

The certainty of evidence for each key question was assessed using the approach described by Grading of Recommendations Assessment, Development and Evaluation (GRADE). We limited GRADE ratings to those key questions which had at least 2 includes. In brief, this approach requires assessment of 4 domains: ROB, consistency, directness, and precision. Additional domains to be used when appropriate are coherence, dose-response association, impact of plausible residual confounders, strength of association (magnitude of effect), and publication bias. We considered these domains qualitatively and assigned a summary rating after discussion by a sub-team of 5 investigators (KG, CW, AL, AG, and BE) as high, moderate, or low strength of evidence. In some cases, high, moderate, or low ratings were impossible or imprudent to make. In these situations, a grade of insufficient was assigned.
PEER REVIEW

A draft version of this report was reviewed by technical experts and clinical leadership. A transcript of their comments and our responses is in Appendix F.
RESULTS

LITERATURE FLOW

We identified 11,245 studies through searches of MEDLINE® (via Ovid®) and EMBASE (Figure 2). After removing duplicates, there were 8,662 articles. After applying inclusion and exclusion criteria to titles and abstracts, 129 articles remained for full-text review. Of these, 5 unique studies were retained for data abstraction. Of the studies retained, 4 were related to diabetes and 1 was related to CHF. Table 2 summarizes the details of the included studies. Common reasons for excluding studies by intervention included virtual care that supplemented rather than replaced in-person care, virtual care interventions delivered by non-prescribing clinicians, and virtual care delivered asynchronously only.
Figure 2. Literature Flow Chart

* Search results from Medline (4,713) and Embase (3,949) were combined.
Table 2. Evidence Profile of Included Studies (n = 5)

| **Number of studies**: 5 randomized studies |  |
| **Number of participants**: 676 participants<sup>a</sup> |  |
| **Regions**: USA (n = 2); Europe (n = 2); Asia (n = 1) |  |
| **Disease focus**: T2DM (n = 4); CHF (n = 1); COPD (n = 0) |  |
| **Patient demographics**: Median age = 58 years old; 25% Women; Race: 92% White (3 studies NR); 10% Black (4 studies NR); 2% Hispanic (4 studies NR); 2% Other (4 studies NR) |  |
| **Intervention mode**:<sup>b</sup> RM + video (n = 1); video (n = 2); RM + telephone (n = 1); telephone (n = 1); |  |
| **Comparisons**:<sup>b</sup> RM + in-person care (n = 2); Usual in-person care(n=3) |  |
| **Outcomes reported**: A1c (n = 4); NYHA class/symptoms (n = 1); hospitalization (n = 3); ED visit (n = 2) |  |
| **Risk of bias**:  |
| **Objective**: High Risk (n = 2), Unclear Risk (n = 1), Low Risk (n = 2) |  |
| **Patient reported**: High Risk (n = 2), Unclear Risk (n = 1), Low Risk (n = 1), Not Applicable (n = 1). |  |

**Abbreviations.** A1c= hemoglobin A1c; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; NR = not reported; NYHA= New York Heart Association; RM= remote monitoring; T2DM = type 2 diabetes mellitus.

<sup>a</sup> One study<sup>27</sup> reported half of the participants (n = 338)

<sup>b</sup> More than 1 category possible per study
KEY QUESTION 1

1A: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of congestive heart failure (CHF) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)?

1B: Does this effect differ by race/ethnicity, gender, age, and rural status?

Key Points

- Only 1 study met the inclusion criteria for synchronous virtual care for chronic management of CHF.
- The 1 included study enrolled 210 patients with CHF and a recent implantation of either an implanted cardio-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) and randomized them to receive quarterly automated asynchronous web-based review and follow-up of telemetry data versus synchronous personal follow-up (in-person vs phone-based) for 1 year. The comparison of the 2 types of synchronous follow-up met our inclusion criteria. A 3-way comparison across study arms found no significant differences in reported composite Packer scores or other clinical outcomes such as mortality, CHF-related admissions, NYHA class, and change in reported quality of life.

- Outcomes based on race/ethnicity, gender, age, and rural status were not reported.

Detailed Findings: KQ 1a

We identified only 1 study that met the inclusion criteria for synchronous virtual care for chronic CHF management and found it to have a high ROB. Based in Germany, this study enrolled 210 patients with CHF with recent placement of an ICD or CRT-D who were then randomized to receive completely asynchronous web-based automated review and follow-up of telemetry data every 3 months (n = 102) or personal physician contact every 3 months in addition to remote monitoring. The personal contact group was further randomized to personal contact via telephone calls (n = 53) or personal contact via in-person visits (n = 55). The primary outcome was the proportion of patients with worse Packer Heart Failure Clinical Composite Response scores at 13 months compared to 1 month after device placement. The Packer composite response score gives a stepwise assessment and incorporates CHF death/hospitalization, change in NYHA class, and self-assessed health status. Secondary outcomes assessed were all-cause mortality, CHF-related hospitalizations, arrhythmias, and change in reported quality of life. There were no significant differences in Packer scores in a 3-way comparison between the telemetry arm compared to the personal contact subgroups (remote + phone vs remote + in-person visit) (p = 0.967). Similarly, there were no significant differences in secondary outcomes in mortality between subgroups (4.9% vs 7.5% vs 3.6%, p = 0.645), CHF-related hospitalization between subgroups (9.8% vs 11.3% vs 12.7%, p = 0.851), the detection of supraventricular
tachycardia between subgroups (17.6% vs 7.5% vs 12.7%, p = 0.216), detection of ventricular tachycardia (19.6% vs 15.1% vs 16.4%, p = 0.752), or reported change in quality of life (p = 0.724). Overall, the authors found that there were no significant differences between the subgroups in any outcome measured.

**Quality of Evidence for KQ 1a**

The single study that met our inclusion criteria\(^\text{28}\) was found to have a high ROB due to low numbers of patients enrolled, an unclear method for patient randomization, and poor description of both patient dropout and how primary outcomes were assessed.

**Detailed Findings: KQ 1b**

The single study that met inclusion criteria\(^\text{28}\) described the age (overall mean 63.8 years) and gender of their patient population (84.3% male); however, details regarding race/ethnicity and rural status were not reported. Furthermore, the authors did not perform any subgroup analyses examining the effect of age or gender on outcomes.

**KEY QUESTION 2**

2A: Among adults, what is the effect of synchronous virtual care (ie, phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of chronic obstructive pulmonary disease (COPD) on key disease-specific clinical outcomes and health care utilization (ie, hospital admission, hospital re-admission, ER visits)?

2B: Does this effect differ by race/ethnicity, gender, age, and rural status?

No studies were identified that addressed KQ 2.
KEY QUESTION 3

3A: Among adults, what is the effect of synchronous virtual care (i.e., phone and/or video) compared to in-person care (or compared to phone if synchronous video care) for chronic management of Type 2 diabetes mellitus (T2DM) on key disease-specific clinical outcomes and health care utilization (i.e., hospital admission, hospital readmission, ER visits)?

3B: Does this effect differ by race/ethnicity, gender, age, and rural status?

Key Points

- Four studies (n = 466) evaluated synchronous chronic care for patients with diabetes in comparison to in-person care. All were conducted in specialty endocrine clinics.
- No studies were conducted in VHA or reported enrolling Veterans.
- Interventions may decrease A1c, but the certainty of evidence is very low. In the 1 adequately powered study, there was no significant effect.
- Minimal data was provided on hospitalizations, ER visits, and utilization.
- Intervention approaches to the use of virtual care varied greatly, from remote monitoring of blood glucose combined with video versus in-person visits, a specialized endocrinology clinic that individually tailored the frequency of virtual visits, to a brief, 3-week intervention to stabilize uncontrolled diabetes remotely.

Characteristics of Included Studies

For KQ 3a, we present the detailed results ordered by outcome: (1) A1c, (2) hospitalizations, (3) ER visits, and (4) number of contacts and utilization.

We identified 4 studies – all of which were randomized trials\textsuperscript{24,27,29,30} – that evaluated the provision of synchronous virtual care compared to in-person care for chronic management of T2DM. Two studies were conducted in the United States,\textsuperscript{24,30} 1 in South Korea\textsuperscript{27} and 1 in Denmark.\textsuperscript{29} One study was conducted with military patients.\textsuperscript{30} Intervention duration varied across studies from fewer than 8 weeks to 52 weeks. Intervention approach varied across the 4 studies in duration and mode of incorporating virtual care into chronic diabetes management. Three studies included 60 or fewer patients\textsuperscript{24,29,30} and 1 study included 338.\textsuperscript{27} Three studies used technology that facilitated synchronous bidirectional communication between the patient and clinician\textsuperscript{27,29,30} and 1 study relied on telephone and email.\textsuperscript{24} Two studies included remote monitoring\textsuperscript{27,30} Additional details on study characteristics are in Appendix B, and intervention characteristics are in Appendix C.
Detailed Findings: KQ 3a

A1c

All 4 studies compared change in A1c reduction from baseline to end of study between synchronous virtual care and in-person study arms (Figure 3).24,27,29,30

The first study27 by Jeong et al was a 24-week 3-arm trial that compared usual care, telemonitoring (remote monitoring with automated clinical decision support with in-person endocrine follow-up appointments), and telemedicine (remote monitoring with automated clinical decision support with video-based endocrine follow-up appointments). They enrolled 338 patients with a baseline mean age of 53. No statistically significant difference was seen at baseline for A1c across groups: usual care (8.39% SD 1.10), telemonitoring (8.21, SD 0.93%), and telemedicine (8.39, SD 1.10). A statistically significant difference was seen for within-group decrease in A1c from baseline to 24 weeks for all groups ranging from -0.66 to -0.81 (p < 0.001). No statistically significant difference was noted for size of A1c reduction across groups: usual care versus telemonitoring groups (p = 0.6127), usual care versus telemedicine (p = 0.162), and telemonitoring versus telemedicine groups (p = 0.343).

The second study24 led by Klingeman et al was a 52-week, 2-arm trial consisting of usual endocrine care versus an experimental group that enrolled 60 patients with T2DM. The setting for the study was an endocrinology clinic at an academic medical center where patient care was provided by endocrinologists. Patients not in the experimental arm received usual care provided by usual clinic endocrinologists. The specialty clinic model in the experimental group included an endocrinologist and nurse educator who focused on patients with advanced diabetes; contact with the patients in this arm was designed to be variable and patient-specific. Pre-planned contacts (via email, phone) were determined at baseline and amended over time, and ad hoc in person visits occurred if clinically required. Contact was individually tailored upon each patient’s outcomes, adverse reactions, and changes in disease state. The control arm received usual endocrine care which included the ability for the patients to contact (via email and phone) clinicians as needed. Hemoglobin A1c levels were noted between groups at baseline usual care (8.9% SD 0.8%) versus specialty clinic model (9.5%, SD 0.9%). Additionally, a greater proportion of White patients were enrolled in the intervention arm (96.6%) compared to the usual care (76.8%) group. Analysis of data at 52 weeks found a greater decrease in A1c with the specialty clinic model of -1.7% (from 9.6 to 7.9%) as compared to the usual endocrine care at 0.3% (from 8.9 to 8.6%) with p = 0.004. Of note, a sensitivity analysis was conducted that dropped data from 1 outlier patient in the usual care group with worsened A1c values (8.3% to 13.5%), but this did not change the results.

The third study29 by Rasmussen et al was a 2-arm trial comparing 3 weeks of brief standard in-person endocrine care versus telemedicine (video-based endocrine care) to stabilize patients with poorly controlled T2DM. They enrolled 40 patients with baseline A1c in standard care group of 8.1% (range 6.1 to 10.7) and 9.0% (7.6 to 12) in the telemedicine group. At 6 months the A1c ranged from 8.1% to 7.2% for the standard care group and 9.1% to 7.7% for the telemedicine group. The percent change in A1c was statistically significant with a decrease of 14.6% in telemedicine and 10.6% in standard care (p = 0.016) across groups. Of note, although this study framed its hypothesis as that “the treatment by telemedicine at home was similar to standard care”, the analysis methods employed did not employ non-inferiority analytic approaches.
The fourth study by Whitlock et al, which tested usual care and telemonitoring visits with a case manager and physician, enrolled 28 patients in a 36-week 2-arm trial consisting of a standard of care control versus experimental telemonitoring group. In this study, both groups were referred for multidisciplinary diabetic education classes, and the experimental group then received weekly telemonitoring with video by a case manager and then monthly telemonitoring by video with study physicians. Standard of care patients received routine in-person care with their primary care clinician. A statistically significant within-group difference (p < 0.05) was noted for the experimental telemonitoring arm from baseline A1c of 9.5 (8.1 to 12.6) to an end A1c of 8.2 (5.7 to 10.2). For the comparator, the mean baseline A1c was 9.5 (8.1 to 11.9) and end A1c was 8.6 (7.1 to 11.9).

Figure 3. Change in A1c Between Intervention and Comparator Arms Across KQ 3a Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>MD [95% CI]</th>
<th>Favor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitlock 2000</td>
<td>Video -1.30</td>
<td>-0.40 [-1.33, 0.53]</td>
<td>Intervention</td>
</tr>
<tr>
<td>Rasmussen 2016</td>
<td>Video -1.37</td>
<td>-0.50 [-1.25, 0.25]</td>
<td>Comparator</td>
</tr>
<tr>
<td>Klingeman 2017</td>
<td>Phone and email -1.60</td>
<td>-1.30 [-2.23, -0.37]</td>
<td>Favor</td>
</tr>
<tr>
<td>Jeong 2018</td>
<td>Remote monitoring + video -0.81</td>
<td>-0.15 [-0.43, 0.13]</td>
<td>Favor</td>
</tr>
</tbody>
</table>

Hospitalizations

Two studies examined hospitalizations. In the study by Jeong et al, only 1 patient in the telemonitoring arm experienced a diabetes complication-related hospitalization, and no patients in the control or telemedicine arms experienced diabetes-related hospitalizations. In the second study by Klingeman et al, 3 patients out of 30 in the experimental arm and 7 patients out of 30 in the control arm experienced a diabetes-related hospital admission.

ER Visits

Two studies examined emergency room (ER) visits. In the first study by Jeong et al, across the 3 study arms, no patients experienced diabetes-related visits to the ER out of the 338 patients enrolled in the study. In the second study by Klingeman et al, no patients in the experimental arm and 1 patient in the control arm experienced a T2DM-related ER visit.

Number of Contacts and Utilization

Three studies reported collecting data on number of contacts and utilization among patients receiving in-person or virtual care.
The study\textsuperscript{24} by Klingeman et al reported on (1) study completion, (2) diabetes education referrals, (3) diabetes-related visits, (4) utilization of modality, and (5) number of interactions and A1c. The study by Klingeman et al designed the experimental arm for variable frequency of contact using a specialty clinic model. Pre-planned contacts (via email, phone call, or visit) were determined at baseline and amended over time; contact was tailored upon each patient’s outcomes, adverse reactions, and changes in disease state; the control arm received usual endocrine care. Klingeman et al reported that when diabetes education visits were combined with clinician diabetes-related visits in the endocrinology clinic, the experimental group had fewer overall visits than the control group. Specifically, the experimental group had 1.5 (SD 0.7) visits versus 3.6 (SD 4.0) visits over 12 months (p = 0.0001). However, the experimental group had significantly more email contacts than in the control arm, with 11.1 (SD 6.4) email interactions in the experimental group and 1.8 (SD 3.5) email interactions in the control group (p < 0.0001). (Note: email communication was a focus in the experimental arm.)

The study by Rasmussen et al, which tested standard care and video consultation for home treatment of T2DM,\textsuperscript{29} reported on (1) study completion, (2) number of visits and missed visits, and (3) consultation time. Study completion did not differ significantly between telemedicine (n = 20) and standard care (n = 20) groups. The telemedicine group had 4.1 visits on average with no missed visits; however, the usual care group had on average 3.8 visits with 13% missed visits. In regards to consultation time, the telemedicine group averaged 18 minutes and the usual care group averaged 23 minutes.

The study by Whitlock et al,\textsuperscript{30} reported no results on number of contacts and utilization despite describing collecting the number of clinic visits before and during the study in the methods.

**Quality of Evidence for KQ 3a**

For the 4 randomized studies, the ROB (Figure 4) for patient-reported outcomes was judged low for 1 study, unclear for 1 study, and high for 1 study; 1 study did not report this type of outcome.\textsuperscript{24,27,29,30} For objective outcomes, ROB was judged low for 2 studies\textsuperscript{27,29} and high for 2 studies.\textsuperscript{24,30} Patterns that led to judgements of low ROB (Figure 5) included (1) noting randomization of study participants; (2) collecting objective outcome data; and (3) general limited expected impact of bias from patient knowledge of treatment arm. Patterns that led to high ROB included (1) missing or unclear data on randomization methods, data collection, and analysis; (2) unblinded treatment arm; (3) no predetermined intervention assessment patterns in the protocol; (4) unclear primary outcomes; and (5) unclear or missing reporting of patient-reported outcomes.
**Figure 4. Risk of Bias Assessment for Included Studies in KQ 3a**

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomization</th>
<th>Allocation Concealment</th>
<th>Baseline Outcome Measure Similar</th>
<th>Baseline Provider Similar</th>
<th>Detection Bias Objective Outcome</th>
<th>Detection Bias Patient-reported outcome</th>
<th>Attrition/Incomplete Outcome Data</th>
<th>Protection Against Contamination</th>
<th>Selective Outcomes Reporting</th>
<th>Other bias</th>
<th>Overall Objective ROB</th>
<th>Overall Patient-reported ROB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeong, 2018</td>
<td>?</td>
<td>+</td>
<td>-</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk of bias</td>
<td>Low risk of bias</td>
</tr>
<tr>
<td>Rasmussen, 2016</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk of bias</td>
<td>Low risk of bias</td>
</tr>
<tr>
<td>Whitlock, 2000</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>High risk of bias</td>
<td>Low risk of bias</td>
</tr>
</tbody>
</table>

**Abbreviations.** ROB = risk of bias.
Detailed Findings: KQ 3b

Only 1 of the included studies reported on subgroup analysis\textsuperscript{27} by patient characteristics. Jeong et al analyzed 2 subgroups of \textit{a priori} interest: gender and age. No statistically significant difference in reduction of A1c was found for men (-0.76 ± 1.11 telemonitoring vs -0.89 ± 1.12 telemedicine; \(p = 0.88\)) or women (-0.46 ± 1.05 vs -0.63 ± 0.87; \(p = 0.16\)). Nor was a statistically significant difference in reduction of A1c seen by age < 55 years of age (-0.63 ± 1.26 telemonitoring vs -0.87 ± 1.15 telemedicine; \(p = 0.21\)) nor with age \(\geq 55\) years (-0.68 ± 0.88 telemonitoring vs -0.73 ± 0.93 telemedicine; \(p = 0.83\)). In addition, Jeong et al reported on additional subgroups of potential interest. High compliance users (defined as users with > 90\% of number of records or data transmitted compared to recommended number of records) had no difference in reduction of A1c versus those with lower compliance levels across the study arms of interest (-0.93 ± 0.99 telemonitoring vs -1.08 ± 0.96; \(p = 0.47\)). Similarly, there was no significant difference in reduction of A1c between patients who had a high school education or less in the telemonitoring (−0.65 ± 0.93) and telemedicine (−0.94%, ±1.1) arms (\(p = 0.26\)).
KEY QUESTION 4: What are the adverse effects of synchronous virtual care for chronic management of CHF, COPD, and T2DM as compared to in-person care (or compared to phone if synchronous video care) on patients (ie, hypoglycemic events), clinical team members (ie, burnout), and clinics (ie, increase in resource costs)?

Detailed Findings: KQ 4

Two studies on T2DM reported adverse events. The study by Jeong et al described 4 groups of adverse events: (1) general events, (2) diabetes-related events, (3) serious events, and (4) biochemical events. Adverse events were noted in the control (n = 33 or 29.20%, in-person appointments at 8, 16, 24 weeks), telemonitoring (n = 30 or 26.55%, in-person appointments at 8, 16, 24 weeks with remote monitoring of blood glucose data), and telemedicine (n = 23 or 20.54%, video visits at 8 and 16 weeks, in-person visit at 24 weeks) arms. Diabetes-related events were noted in the control (n = 7 or 6.19%), telemonitoring (n = 7 or 6.19%), and telemedicine (n = 3 or 2.68%) arms. Serious reported adverse events were noted in the control (n = 2 or 1.7%), telemonitoring (n = 2 or 1.70%), and telemedicine (n = 1 or 0.90%) arms, and included angina pectoris, rotator cuff syndrome, malignant hepatic neoplasm, skin ulcer, and hematuria. Biochemical parameters for serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine levels were measured and samples obtained at baseline and 24 weeks; each value was classified as normal or abnormal. ALT was the only parameter that showed a significant worsening from a normal baseline across groups; specifically, 0 telemonitoring arm participants (0%) versus 7 telemedicine participants (6.7%) (p = 0.014) experienced a worsening of ALT values. Authors also noted that 5 patients (4.8%) in the control arm experienced a decline in ALT from a baseline normal value. The study by Klingeman et al described 2 types of adverse events: (1) severe hypoglycemia and (2) foot ulcers. Severe hypoglycemia was noted in the experimental (n = 1 or 3.3%) arm but not in the control (n = 0 or 0%) arm. Foot ulcer was noted in the experimental (n = 1 or 3.3%) and control (n = 3 or 10%) arms.
SUMMARY AND DISCUSSION

SUMMARY OF EVIDENCE BY KEY QUESTION

**KQ 1a:** The 1 study that met inclusion criteria enrolled patients with CHF who had a recent implantation of either an ICD or a CRT-D and randomized them to receive quarterly automated web-based review and follow-up of telemetry data versus synchronous personal follow-up (in-person vs phone-based) for 1 year and found no significant differences in clinical outcomes between the 3 groups. The certainty of evidence was downgraded to very low certainty because of serious ROB, indirectness, and imprecision (Table 3).

**KQ 1b:** The included study did not report outcomes by race/ethnicity, gender, age, and rural status.

**KQ 2a, KQ 2b:** We found no studies on the effect of synchronous virtual compared to in-person care for chronic management of COPD.

**KQ 3a:** We identified 4 studies (n = 466 participants)\(^{24,27,29,30}\) that evaluated the provision of synchronous virtual care compared to in-person care for chronic management of T2DM. The 1 adequately powered, low ROB study found no statistically significant reduction in A1c between synchronous virtual care compared to usual care and asynchronous virtual care. Overall, findings from this review indicate that the impact of virtual care as a substitute for in-person care on A1c remains unclear. Hospitalizations, ER visits, number of contacts, and utilization were not uniformly reported across studies. Number of contacts and utilization varied by study and were not consistently reported. The certainty of evidence was downgraded to very low certainty because of serious ROB, indirectness, and imprecision.

**KQ 3b:** The 1 adequately powered, low ROB study was the only to report subgroup analyses by patient characteristics of interest, specifically age and gender. They found no statistically significant difference in reduction of A1c by age (< 55 years of age, ≥ 55 years) or gender.

**KQ 4:** Two of the studies on diabetes reported adverse events. There were small event rates and no evidence of differences by study arms.

### Table 3. Certainty of Evidence for KQ 1 and 3

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Number of Studies (N patients)</th>
<th>Range of Effects</th>
<th>Certainty of Evidence (Rationale)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type 2 Diabetes Mellitus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A1c</td>
<td>4 randomized trials (339 patients)</td>
<td>Range from -0.15 to -1.30 difference in mean difference between intervention and comparator A1c</td>
<td>Very low certainty that virtual care has an effect on A1c (rated down for serious risk of bias, indirectness, and imprecision)</td>
</tr>
<tr>
<td>Hospital admission</td>
<td>2 randomized trials (285 patients)</td>
<td>Range from 0 to 3 admissions in the intervention arm and 0 to 7 admissions in comparator arm</td>
<td>Very low certainty that virtual care has an effect on hospital admissions (rated down for serious risk of bias, indirectness, and imprecision)</td>
</tr>
<tr>
<td>Outcome</td>
<td>Number of Studies (N patients)</td>
<td>Range of Effects</td>
<td>Certainty of Evidence (Rationale)</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Emergency department visits</td>
<td>2 randomized trials (285 patients)</td>
<td>0 emergency department visits in the intervention arms and range from 0 to 1 visit in comparator arm</td>
<td>Very low certainty that virtual care has an effect on emergency department attendance (rated down for serious risk of bias, indirectness, and imprecision)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA class/symptoms</td>
<td>1 randomized trial (219 patients)</td>
<td>Between-group difference p = 0.967</td>
<td>Very low certainty that virtual care has an effect on NYHA class/symptoms (rated down for serious risk of bias, inconsistency, indirectness, and imprecision)</td>
</tr>
<tr>
<td>Hospital admission</td>
<td>1 randomized trial 219 patients</td>
<td>RM (9.8%) vs RM + phone (11.3%) vs in-person visit (12.7%), p = 0.851</td>
<td>Very low certainty that virtual care has an effect on hospital admission (rated down for serious risk of bias, inconsistency, indirectness, and imprecision)</td>
</tr>
</tbody>
</table>

Abbreviations. A1c = Hemoglobin A1c; NYHA = New York Heart Association; RM = Remote Monitoring

**PRIOR SYSTEMATIC REVIEWS**

A 2016 AHRQ evidence map found 58 existing systematic reviews supporting the use of telehealth interventions for communication/counseling or remote monitoring for chronic conditions. Previous systematic reviews have examined various ways of utilizing virtual care modalities in the context of these conditions of interest, but none focused on replacing in-person care with virtual visits. Our review sought to extend the existing literature by addressing telehealth as a replacement for in-person care in chronic disease management. We found scant evidence examining chronic disease management delivered by synchronous virtual care compared to in-person delivery for T2DM, COPD, and CHF.

Based on prior reviews, there is evidence that virtual care as an *adjunctive* strategy to typical in-person care can be associated with a decrease in A1c in patients with both type 1 and type 2 diabetes. For example, 1 systematic review by Hu et al included studies using various strategies such as remote monitoring, smart device, software, or web-based applications for patients with type I and II diabetes which led to decreased hemoglobin A1c compared to control. Additionally, Lee et al found a 0.43% reduction in A1c in patients with T2DM at 6 months across 107 randomized control trials with implementation of telemedicine strategies such as tele-monitoring, tele-education, or tele-consultation delivered by a variety of disciplines in comparison to usual care. This is also supported by an umbrella review of 95 systematic reviews for patients with type 1 and type 2 diabetes noting a reduction in A1c by 0.2-0.4% when using mHealth (messaging or mobile applications) and virtual care (synchronous electronic communication) specifically. Polisena et al completed a systematic review on home remote monitoring and telephone support for patients with diabetes. The home remote monitoring led to a decrease in A1c and a decrease in overall hospital utilization and mixed emergency department use. The telephone support group had mixed results related to A1c with a non-significant effect on hospital and emergency department utilization (based on a single study for each). Utilization was not specifically related to T2DM complications. Patient satisfaction was equal to or improved in both groups compared to usual care.

While we only found 1 study on virtual care for chronic management of heart failure as a substitution for in-person care, prior systematic reviews report on the impact of other types of
virtual care on heart failure outcomes. A systematic review by Yun et al.\textsuperscript{36} included 37 studies evaluating telemonitoring which found reductions in all-cause and heart failure-related mortality compared to usual care. The same study also observed a non-statistically significant trend towards decreased heart failure-related hospitalizations, but no differences in all-cause hospitalizations. The Yun et al. review showed improvement in the quality of life, but not patient satisfaction for the intervention compared to usual care. Similarly, an umbrella review on telemonitoring for heart failure by Bashi et al.\textsuperscript{37} found reductions in hospitalizations and mortality with increased quality of life. However, a systematic review of mHealth interventions (mobile devices for monitoring or messaging) with heart failure patients found mixed results for all-cause and cardiovascular mortality, heart failure-related hospitalizations and NYHA classification score.\textsuperscript{38}

Overall, there is a strong body of evidence that virtual care modalities can improve health outcomes through the supplementation of in-person management of certain chronic diseases, particularly with approaches such as remote monitoring and patient education. Our review sought to build on this existing body of literature by evaluating the effectiveness of virtual care-delivered visits as a substitute for in-person visits for chronic disease management. However, we found that the research in this field remains insufficient and methodologically inconsistent.

**HORIZON SCAN**

Given the limited amount of existing literature we identified that addressed our key question, we sought to assess the pool of ongoing studies in the pipeline that would add relevant findings in the near future. To conduct such a scan of the literature on the horizon, we applied our previously developed search terms to the Cochrane Central Register of Controlled Trials. This search identified 1,787 unique records (see Table 4). At least 1 reviewer screened these at title and abstract. Included records were verified by a second reviewer.

We found only 3 records\textsuperscript{39-41} that referenced studies without published results in our horizon scan (see Table 4). Studies that may potentially meet the inclusion criteria of our systemic review. All 3 of these studies are randomized controlled trials that were designed before the COVID-19 pandemic. Two of the 3 studies focus on T2DM\textsuperscript{39,40} while the other is on CHF.\textsuperscript{41} One of the T2DM studies is a non-inferiority study\textsuperscript{40}; however, it is being conducted in Brazil (a non-OECD country) and therefore the findings may not be applicable to the Veteran population. The other T2DM study\textsuperscript{39} is specifically focused on reducing emergency diabetes care for older (> 50 years) African Americans. The CHF study by Komkov et al. has very limited detail. Thus, it appears that there is little trial-based research currently in the pipeline to inform our key questions in this review.

**Table 4. Ongoing Studies on Virtual Care for Chronic Conditions**

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Recruitment target</th>
<th>Disease state</th>
<th>Intervention/Comparator</th>
<th>Planned duration</th>
<th>Clinical trials #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rovner, 2018\textsuperscript{39}</td>
<td>African Americans, &gt; 50 years, T1DM or T2DM, after DM-related emergency department visit</td>
<td>T2DM</td>
<td>Multi-component intervention including behavioral activation and the facilitation of telehealth visits with</td>
<td>12 months</td>
<td>NCT03466866</td>
</tr>
</tbody>
</table>
Virtual Care for the Longitudinal Management of Chronic Conditions

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Duration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodrigues, 2019&lt;sup&gt;40&lt;/sup&gt;</td>
<td>Patients with T2DM, &gt;18 years, referred from primary care</td>
<td>Teleconsultation with endocrinologist by video vs face-to-face</td>
<td>T2DM</td>
<td>unclear</td>
<td>WHO Clinical Trials Registry ID: RBR-8gpgyd</td>
</tr>
<tr>
<td>Komkov, date unknown&lt;sup&gt;41&lt;/sup&gt;</td>
<td>Patients with CHF discharged from the hospital</td>
<td>Short-term education + active telephone calls by physician vs usual care</td>
<td>CHF</td>
<td>12 months</td>
<td>unknown</td>
</tr>
</tbody>
</table>

**Abbreviations.** CHF = congestive heart failure; DM = diabetes mellitus; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; WHO = World Health Organization.

**CLINICAL AND POLICY IMPLICATIONS**

We found limited literature evaluating the effect of synchronous virtual care compared to in-person care for chronic disease management of common conditions, namely T2DM, COPD, and CHF. Among the included studies, there was significant heterogeneity around the structure, purpose, and delivery of virtual care visits. While not statistically significant and with very low certainty of evidence, our analysis suggested a trend toward greater A1c reduction among virtual care interventions versus comparators. The clinical significance of this finding is unknown. In addition, the generalizability of these findings is limited as all included studies took place in specialty care clinics whereas much of the long-term management for chronic conditions such as T2DM, CHF, and COPD occurs within the context of primary care. Primary care teams provide care for multiple conditions simultaneously which may not support the single disease-focused care described in the included studies.

The COVID-19 pandemic led to an increase in the use of virtual care as a way of making health care more accessible to patients while reducing potential infection risk associated with in-person care.<sup>42</sup> Specifically, the pandemic necessitated replacement of in-person care with virtual care, rather than simply supplementing existing visits. The significant shift in patient care delivery from in-person to virtual care has impacted clinical workflows, workforce needs, and patient experience. However, there is currently a paucity of trial data to describe the outcomes associated with replacing in-person care with virtual care for chronic disease management or to recommend substituting video visits as the standard of care for managing CHF, COPD, or T2DM moving forward. In addition, none of the included studies evaluated patient satisfaction with this change in patient care delivery. Ultimately, it will be critical to clarify if the scientific question of interest is whether virtual care delivery for chronic conditions is more effective than in-person or if it is as effective as in-person care. The difference between these objectives will need to drive study design. A recent commentary by Hertzer and Pronovost<sup>43</sup> pointed out that a better understanding of virtual care with respect to patient safety, effectiveness, efficiency, and equity will be necessary in order for optimal incorporation into clinical practice.
LIMITATIONS

Our findings should be considered within the context of limitations of the included studies and of our methodologic approach.

Limitations of Identified Literature

Publication Bias

Given the small number of studies we identified, statistical methods to detect publication bias were not conducted. While it is possible that individual health systems or clinics have conducted quality improvement studies evaluating differences in experiences between synchronous and in-person care – especially during the COVID-19 pandemic – we suspect it is unlikely that studies meeting EPOC criteria on this intervention have not been published given the recent emphasis on the role of virtual care.

Study Quality

We identified few studies overall and most had fewer than 100 patients and were assessed as unclear or high ROB. Intervention core components, intervention fidelity, or the impact of intervention on clinical workflow were not reported by any study. In addition, the interactions between clinicians and patients during virtual care episodes were not adequately or explicitly described. These omissions limit the interpretation and replication of evaluated interventions. While all studies for T2DM reported change in A1c, this is likely inappropriate for shorter durations of follow-up. Taking the standard duration for measuring changes from diabetes chronic management into account, studies should be at least 6 months in length, while durations of 12 months would be preferable. The majority of our outcomes of interest were not consistently reported across the studies. For example, while several studies provided some information on utilization and adverse events, this information on outcomes was not consistently or thoroughly reported. Only 1 study by Jeong et al27 had an optimal study design for our question regarding the effectiveness of synchronous virtual care compared to in-person care; the other included studies featured this comparison as a secondary focus or delivered the virtual care intervention with co-interventions such as remote monitoring and other clinical activities.

Heterogeneity

Heterogeneity was noted across the identified literature. First, included virtual care interventions used different virtual care modalities (eg, email, phone, video), with different hardware, delivered via different numbers of clinical interactions between patients and clinicians, and over a wide range of intervention durations. Second, studies occurred in different health care systems and countries, which likely have varied broadband access, existing virtual care infrastructure, clinical resources, and workflow processes. Finally, the identified interventions demonstrated marked variation around the clinical focus (eg, short-term stabilization of recently hospitalized poorly controlled diabetes, longer-term management of patients with diabetes not on insulin) and team structure of virtual care delivery (eg, clinicians alone vs nurses with clinician consultation).
Limitations of Our Methodologic Approach

Our review benefited from being protocol driven, leveraging input from an expert panel consisting of clinicians and virtual care researchers, identifying disease-specific clinical outcomes, using a conceptual model to guide understanding of virtual care modalities, and using a detailed approach to categorizing and defining virtual care components in chronic disease self-management. Despite these strengths, limitations exist to our approach. We only included studies that met EPOC criteria in this review; however, observational studies may have findings relevant to the provision of synchronous virtual care for chronic illness management. Only 6 studies were excluded due to study design. It is possible that additional observational studies conducted since the onset of the COVID-19 pandemic may provide useful information (e.g., NCT02788903). In addition, we focused this review on 3 of the most prevalent chronic diseases, but there may be appropriately designed studies that targeted other conditions that we did not include. Finally, we only included studies conducted in OECD countries, and as a result we may have missed relevant studies not conducted in these countries.

Applicability of Findings to the VA Population

None of the included studies were conducted in VHA or reported specifically targeting Veterans. However, 1 study among patients with T2DM occurred in a military setting with an average age of 63 years. Two studies were conducted in countries with nationalized health care (i.e., South Korea, Denmark), which may increase relevancy to VHA. Identified studies included primarily older participants, which is similar to the population of Veterans who have chronic disease.

RESEARCH GAPS

We identified several areas that are worthy of further exploration in order to strengthen future research in this area. To systematically identify these gaps in the current literature, we used an existing framework (Table 5) by Robinson and colleagues44 which proposes to identify gaps categorically using the PICOTS framework (population, intervention, comparator, outcome, timing, and setting). In addition, they include standardized reasons that the current literature is insufficient to answer the question at hand (insufficient or imprecise information, biased information, inconsistency, and/or not the right information).

Overall, there are 5 key areas in which future research on this topic could fill existing gaps and/or could improve the approach. First, and perhaps most importantly, virtual care interventions should be thoroughly described in order to be replicated (e.g., number of patient contacts, the type of training for clinician using virtual care) and to determine if findings are generalizable to specific clinical setting. Guidance exists on mobile and web-based interventions which may provide indirect suggestions about key characteristics for virtual care intervention description.45 Further efforts to outline key characteristics of virtual care interventions could be valuable. Second, there is a need to evaluate how best to integrate virtual care as a substitute for in-person care (e.g., replace all vs a portion), when to include other adjunctive virtual care technologies (e.g., remote monitoring), and in which clinical settings (e.g., primary care vs specialty care settings) as the challenges and effectiveness can be expected to vary across settings with different workflow patterns, clinical resources, and competing clinical demands. Third, outcomes varied across included studies and omitted some key outcomes relevant to interpreting the benefits and risks of this type of intervention including impact on clinical
workflow, patient satisfaction with virtual care experience, and subsequent utilization. Fourth, investigators should consider utilization of non-inferiority analytic approaches when, in fact, the question at hand is whether or not virtually delivered care is as good as in-person delivered care. Finally, investigators should be encouraged to consider a priori identified subgroup evaluations or make individual patient-level data available for future combined analyses that could identify which patient-level characteristics are associated with better outcomes with virtual care as a substitute for in-person care. The VA is well-positioned to conduct needed evaluations of synchronous virtual care given its well-established virtual care infrastructure, uptake of virtual visits, regular assessment of patient satisfaction, and available administrative data. Such information could guide clinics and health care systems to offer optimal patient-centered virtual care delivery.

A critical concern about the proliferation and acceleration of virtual modalities to deliver health care is the potential to introduce or increase existing health care access disparities. Individuals without camera-ready devices, adequate broad-band internet connections, or comfort with technology will have greater challenges in fully engaging in virtual health care offerings. This disparity may be more common amongst some patient populations (eg, rural dwelling, older age, racial/ethnic underrepresented groups) and may exacerbate historically inequitable treatment and institutional racism by the medical establishment. To adequately study such disparities in future systematic reviews, specific methodological approaches are needed. As noted above, primary research studies must include adequately powered a priori subgroup analysis of patient populations of interest and include enhanced recruitment and retention strategies to achieve enrollment targets. In addition, reporting outcomes by subpopulation could support hypothesis generation for future study even when not adequately powered for definitive analysis. Reporting findings by subpopulation and making patient-level data available for individual patient data meta-analysis could support the ability to generate meaningful evidence synthesis about effect variation by patient-level characteristics. New platforms and open access websites have developed to enable the sharing of deidentified datasets for such purposes. Such steps would allow future research to address concerns about equitable benefit and access to virtual care.

Table 5. Evidence Gaps and Areas for Future Research Consideration

<table>
<thead>
<tr>
<th>Evidence Gap/Area for Future Exploration</th>
<th>Reason</th>
<th>Types of Studies to Consider</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Patients with poorly controlled chronic conditions</td>
<td>Insufficient information/ Not the right information</td>
<td>Well-designed subgroup analyses or individual patient-data meta-analysis from randomized trials</td>
</tr>
<tr>
<td>• Patients with well-controlled chronic conditions</td>
<td></td>
<td>Qualitative and mixed methods studies</td>
</tr>
<tr>
<td>• Patients with various social/digital determinants of health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Patients who are earlier in their course of chronic illness or at various stages of disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Video-based and/or phone-based care to replace some portion of in-person all chronic</td>
<td>Insufficient or imprecise information</td>
<td>Randomized trials Non-randomized trials</td>
</tr>
</tbody>
</table>
Virtual modalities such as video or telephone have increasingly been used to replace in-person clinic visits with prescribing clinicians for the management of chronic conditions, particularly during the COVID-19 pandemic. However, currently there is scant evidence of the effect of virtual care as a replacement for in-person visits in the context of common chronic conditions such as T2DM or CHF, and no evidence for COPD. Health care systems need evidence-based guidance about the effect of well-described virtual care interventions in order to deliver high-quality care using the right modality for the right patients with the right clinical condition at the right time.
REFERENCES


44. Robinson KA, Saldanha Ij Fau - McKoy NA, McKoy NA. Development of a framework to identify research gaps from systematic reviews. (1878-5921 (Electronic)).